Merck’s newly authorized molnupiravir treatment logged sales of $952 million in the fourth quarter, the first period when the drug contributed revenue. Meanwhile, sales of Covid-19 antibodies for Lilly grew by 22% year over year to $1.06 billion, although the company is now facing new restrictions on how they are used against the Omicron variant.
Those trends added to overall sales growth for both companies—with Merck posting an especially strong 24% increase—producing adjusted earnings results that beat Wall Street analysts’ expectations. Both companies’ shares were down in premarket trading Thursday.
Merck’s and Lilly’s Covid-19 drug sales reflect how the rise and fall of the variants behind successive waves of the pandemic have forced changes to treatment approaches. Merck said it expects sales this year of $5 billion to $6 billion from molnupiravir, a treatment taken at home that aims to prevent severe illness. Use of Lilly’s antibodies, on the other hand, has been curbed by new regulatory guidance.
The Food and Drug Administration authorized Lilly’s cocktail of two antibodies, etesevimab and bamlanivimab, a year ago. As Covid-19 mutated, however, early testing indicated it was unlikely to work well against Omicron, and the FDA has said the antibodies shouldn’t be used right now because of the new variant’s prevalence.
Regen-Cov, a drug from Regeneron Pharmaceuticals Inc. that works similarly to the Lilly treatments, has also been limited by the FDA.
Meanwhile, newer drugs from Merck and Pfizer Inc. have shown more potential to fight the virus in its latest dominant form.
Merck’s molnupiravir, co-developed with Ridgeback Biotherapeutics LP, was cleared for use by the FDA in December for adults at high risk of severe disease, becoming one of the few available drugs that people can take at home soon after a Covid-19 diagnosis to try to stave off bad outcomes.
Sales of Covid-19 antibodies for Lilly grew by 22% year over year to $1.06 billion.
Photo: vincent kessler/Reuters
A key study had shown molnupiravir was 30% effective at reducing the risk of hospitalization and death from Covid-19.
Last week, Merck and Ridgeback said that the pill was active against the Omicron variant in laboratory tests, an encouraging sign as higher case loads caused by the variant’s spread persist. Pfizer’s Paxlovid pill has also shown efficacy against Omicron in lab tests, Pfizer said last month.
Still, researchers and regulators have cautioned that the newest pills might not be a magic bullet for reducing the harm the virus causes. Some worry that the virus will mutate to gain resistance to the treatments.
Pfizer and Merck researchers have said they didn’t see resistance develop during the clinical trials evaluating the pills.
Overall, Merck’s sales for October through December were $13.52 billion, up from $10.95 billion 12 months before. Its adjusted earnings were $1.80 a share after stripping out one-time items. Analysts had been forecasting revenue of $13.16 billion and adjusted earnings of $1.53 a share, according to FactSet’s survey.
Excluding revenue from Covid-19 antibodies, Lilly’s sales grew by 6%. Total revenue was $8 billion, yielding adjusted earnings of $2.49 a share. Wall Street forecasters were expecting revenue of $7.69 billion and adjusted earnings of $2.45 a share.
For the rest of 2022, Lilly reaffirmed a previous forecast for adjusted earnings of $8.50 a share to $8.65 a share. Merck said it is expecting full-year per-share adjusted earnings of $7.12 to $7.27, based on anticipated sales of $56.1 billion to $57.6 billion.
Write to Matt Grossman at [email protected]
Copyright ©2022 Dow Jones & Company, Inc. All Rights Reserved. 87990cbe856818d5eddac44c7b1cdeb8
